Table 2.
Cumulative incidence ratio (risk ratio) for posterior capsule opacification and Nd:YAG capsulotomy, and mean differences in logMAR levels over 36-month follow-up between the Acrysof (SN60WF, reference) and iSert groups (XY-1 or 251/255, index).
| Comparison | iSert XY-1 vs. Acrysof (SN60WF) | iSert 251/255 vs. Acrysof (SN60WF) | ||
|---|---|---|---|---|
| Analyses | Crude | Adjusted*1 | Crude | Adjusted*1 |
| Effect estimate | Risk ratio (95% CI) | Risk ratio (95% CI) | ||
| Posterior capsule opacification | ||||
| 36 months | 1.76 (0.93, 3.35) | 0.99 (0.43, 2.28) | 2.98 (1.81, 4.92) | 2.39 (1.50, 3.79) |
| Nd:YAG capsulotomy | ||||
| 36 months | 3.21 (1.05, 9.80) | 4.42 (1.18, 16.5) | 3.50 (1.20, 10.21) | 4.56 (1.01, 20.5) |
| LogMAR, Mean Difference (95% CI) | ||||
| 3 months | 0.00 (− 0.26, 0.26) | 0.00 (− 0.26, 0.25) | − 0.14 (− 0.43, 0.15) | − 0.14 (− 0.43, 0.14) |
| 6 months | − 0.09 (− 0.36, 0.17) | − 0.07 (− 0.33, 0.19) | − 0.15 (− 0.43, 0.13) | − 0.15 (− 0.43, 0.12) |
| 12 months | − 0.05 (− 0.33, 0.23) | − 0.04 (− 0.31, 0.24) | − 0.09 (− 0.38, 0.21) | − 0.10 (− 0.39, 0.19) |
| 36 months | − 0.09 (− 0.42, 0.24) | − 0.07 (− 0.40, 0.26) | − 0.10 (− 0.42, 0.23) | − 0.12 (− 0.44, 0.20) |
For the adjusted model, age, sex, diabetes mellitus, and sarcoidosis were included as covariates (*1).
SD standard deviation, CI confidence interval, LogMAR log of the minimum angle of resolution.